艾司西酞普兰治疗精神分裂症后抑郁的疗效及安全性分析

Efficacy and safety analysis of Escitalopram in treatment of post- schizophrenic depression

目的:探讨艾司西酞普兰治疗精神分裂症后抑郁的临床疗效及安全性。方法:将44例精神分裂症后抑郁患者,随机分为对照组(西酞普兰)和观察组(艾司西酞普兰),治疗6周后,依据汉密尔顿抑郁量表(HAMD)、阳性与阴性症状量表(PANSS)、副反应量表(TESS),对两组患者临床疗效及治疗期间不良反应,进行观察和比较。结果:与对照组相比,观察组患者治疗后HAMD评分、各因子PANSS评分及PANSS总分均明显降低,P<0.05。治疗期间都没有出现严重不良反应。结论:艾司西酞普兰治疗精神分裂症后抑郁的疗效显著、不良反应少、安全性高,值得临床广泛推广。

Objective：To study the clinical efficacy and safety of Escitalopram in treatment of post-schizophrenic depression. Methods：44 patients with post-schizophrenic depression were randomized into the control group （ Citalopram） and observation group （ Escitalopram） . After six-week treatment, the clinical efficacy and side effects during the treatment period in the two groups were observed and compared according to the Hamilton depression scale （ HAMD） , positive and negative symptom scale （ PANSS） , and treatment emergent symptom scale （TESS）. Results： Compared with control group, the HAMD scores, PANSS scores and PANSS total scores the observation group after the treatment were significantly reduced （P〈0. 05）. There were no serious adverse reactions during the treatment period. Conclusions：The treatment of Escitalopram for post-schizophrenic depression has the significant efficacy, less adverse reactions and high safety, and is worthy of clinical promotion.